Fermenta Q1FY27 Revenue Flat QoQ at ₹126.2 Cr, Down 13% YoY
Fermenta Biotech's Q1FY27 consolidated revenue was ₹126.2 crore, flat QoQ and down 13% YoY. EBITDA stood at ₹22.4 crore (down 11% QoQ, 39% YoY), and PAT at ₹9.5 crore (down 49% QoQ, 56% YoY). Human nutrition volumes rose 18% QoQ, and India's share in revenue increased to 47%. Post-quarter, VITADEE Green® received FSSAI approval.
The decline in YoY revenue and EBITDA, coupled with a significant drop in profit after tax, suggests a material impact on the company's financial performance. However, the sequential stability in revenue and positive commentary on future growth drivers like VITADEE Green® mitigate a high impact.
The results show a year-on-year decline in revenue and profit, impacted by factors like lower realisations in animal nutrition and the absence of one-time income from the previous year. While there are positive developments like human nutrition volume growth and FSSAI approval, the overall financial performance indicates a neutral outlook.
Fermenta Biotech Limited announced its unaudited consolidated financial results for the first quarter of FY27 (ended June 30, 2026).
Consolidated revenue, including real estate, was ₹126.2 crore, which was flat compared to the previous quarter (Q4FY26) but down 13% year-on-year (YoY) compared to Q1FY26. Consolidated EBITDA was ₹22.4 crore, down 11% QoQ and 39% YoY. Profit after tax stood at ₹9.5 crore, a significant decrease of 49% QoQ and 56% YoY.
Excluding real estate, consolidated revenue for Q1FY27 was ₹124.3 crore, flat QoQ and down 12% YoY. EBITDA, excluding real estate, was ₹22.3 crore, down 10% QoQ and 37% YoY. The company noted that the year-on-year comparisons are against an exceptionally strong Q1FY26, which included non-recurring income such as ₹2.7 crore from an insurance claim and ₹1.6 crore from real estate value unlocking.
The company highlighted growth in specific segments. Human nutrition volumes increased by 18% sequentially, contributing 61% to the consolidated revenue at ₹76.5 crore. Other APIs and Intermediates grew 18% YoY to ₹11.6 crore, and Green Chemistry Solutions/Enzymes saw a 15% YoY increase to ₹2.3 crore. The domestic market's share in consolidated revenue rose to 47% from 35% a year earlier.
Animal nutrition remained a soft spot, with volumes down 52% QoQ and 20% YoY, and average realisations down 40% YoY. The company stated a focus on volume discipline over chasing weak prices in this segment.
Key developments post-quarter include the FSSAI approval for VITADEE Green®, Fermenta's plant-source Vitamin D3, on July 6, 2026, for use in health supplements, nutraceuticals, food products, and food fortification. In June 2026, Fermenta was recognized as one of India's Great Mid-size Workplaces™ 2026, ranking 7th nationwide.
Prashant Nagre, Managing Director, commented that the quarter was about building rather than harvesting, with sequential volume growth in human nutrition and strengthening of the Indian market. He expressed confidence due to the FSSAI approval for VITADEE Green® and the company's workplace ranking, emphasizing a focus on scaling the human nutrition business and broadening the earnings base.
What to do with a filing like this
Fermenta Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fermenta Biotech Limited. Read the original for the full detail.